Main S&T results Sample Clauses

Main S&T results. A- COHORTS STUDIES A large clinical database, based on (1) population studies, (2) cross-sectional and prospective studies of patients with overt disease or at risk or (3) patients enrolled in randomized clinical trials, have been constructed to validate the association of ‘omics’-based biomarkers with the risk of developing heart failure and co-morbidities. Eligible studies for inclusion received ethical approval, have baseline information on cardiovascular risk factors available and if the subsequent follow-up includes fatal and nonfatal outcomes, including heart failure. Population studies, patient cohorts and randomized controlled trials are eligible for inclusion in the common database. Currently, the HOMAGE database includes 43133 subjects, from 20 studies in 8 European countries. Data from healthy subjects were obtained from 3 population studies in France, Belgium and Italy (n=7124). The database also consists of patients with heart failure (n=3690), from 3 cohorts in UK and Spain. Eight cohorts in patients with cardiovascular risk factors (n=5829) from France, Austria, the Netherlands and Italy were also included. Finally, data from 6 randomized controlled trials (n=26490) in heart failure patients, hypertensive patients and patients with high cardiovascular risk, from Austria, Ireland, the Netherlands, and UK, were included in the HOMAGE database. At this moment, follow-up data are available in 12 of the 20 studies (n=38144).Overall partners have collected and supplied information on >45,000 patients regrouped within population cohorts (n=3; 7,134 individuals), Heart failure patients cohorts (n=3; 3,690 individuals), at CV-risk patient cohorts (n=8; 5,829 patients) and RCTs (n=6; 26,490 patients) with up to 10 years follow-up. A common HOMAGE data dictionary has been established. A SOP was developed on guidelines for common database management and analysis. It proposes a definition of events within the cohorts contributed to HOMAGE. A detailed description of the database and corresponding biosamples is available. The database is extensively described in the design paper. The definition of new onset heart failure (“Cases”) and of control patients with no new onset heart failure (“Controls”), was defined. Two definitions were chosen by the consortium to select the “new onset HF” cases and corresponding controls in retrospective studies: - “hard definition of hospitalization for heart failure” that lead to the selection of 982 cases and 1969 controls...
Sample 1
AutoNDA by SimpleDocs
Main S&T results. The project started a number of activities in parallel from each of the three scientific themes: Theme “Allergens” Pre-clinical development of a series of hypo-allergenic candidates for fish parvalbumin and peach lipid transfer protein. Theme “Clinical studies” Clinical characterization of fish allergic patients and fruit allergic patients from across Europe Theme “Immunology” Identification of dominant T-cell epitopes of parvalbumin and lipid transfer protein. Theme “Allergens” In the development of suitable vaccine candidates three major criteria were evaluated:  Hypo-allergenicity  Immunogenicity  Stability For fish parvalbumin the parvalbumin of carp, Cyp c 1, was chosen. Natural purified Cyp c 1 (nCyp c 1) and wild-type recombinant Cyp c 1 (rCyp c 1) were used as control allergenic reference molecules to assess hypo-allergenicity, immunogenicity and stability of two candidate hypo- allergenic variants:
Sample 1

Related to Main S&T results

  • Test Results The employer, upon request from an employee or former employee, will provide the confidential written report issued pursuant to 4.9 of the Canadian Model in respect to that employee or former employee.

  • Positive Test Results In the event an employee tests positive for drug use, the employee will be provided, in writing, notice of their right to explain the test results. The employee may indicate any relevant circumstance, including over the counter or prescription medication taken within the last thirty (30) days, or any other information relevant to the reliability of, or explanation for, a positive test result.

  • Audit Results If an audit by a Party determines that an overpayment or an underpayment has occurred, a notice of such overpayment or underpayment shall be given to the other Party together with those records from the audit which support such determination.

  • ADVERTISING RESULTS The prior written approval of the Commissioner is required in order for results of the Bid to be used by the Contractor as part of any commercial advertising. The Contractor shall also obtain the prior written approval of the Commissioner relative to the Bid or Contract for press or other media releases.

  • - OWNERSHIP/USE OF THE RESULTS II.3.1 Unless stipulated otherwise in this agreement, ownership of the results of the action, including industrial and intellectual property rights, and of the reports and other documents relating to it shall be vested in the beneficiary.

  • Positive Test Result Where there has been a positive test result in a confirmatory test and in any confirmatory retest (if the employee requested one), the Employer will do the following unless the employee has furnished a legitimate medical reason for the positive test result:

  • New Businesses 48 9.15 Government Regulations........................................48 9.16

  • Publication of Results The National Aeronautics and Space Act (51 U.S.C. § 20112) requires NASA to provide for the widest practicable and appropriate dissemination of information concerning its activities and the results thereof. As such, NASA may publish unclassified and non-Proprietary Data resulting from work performed under this Agreement. The Parties will coordinate publication of results allowing a reasonable time to review and comment.

  • BID TABULATION AND RESULTS Bid tabulations shall be available thirty (30) days after opening on the Orange County website at: xxxx://xxxx.xxxx.xxx/orangebids/bidresults/results.asp or upon notice of intended action, whichever is sooner.

  • Freedom to Pursue Opportunities The Parties expressly acknowledge and agree that: (i) Sponsor and each Sponsor Director (and each Affiliate thereof) has the right to, and shall not have any duty (contractual or otherwise) to (and none of the following shall be deemed to be wrongful or improper), (x) directly or indirectly engage in the same or similar business activities or lines of business as the Parent Parties or any of their respective Subsidiaries, including those deemed to be competing with the Parent Parties or any of their respective Subsidiaries, or (y) directly or indirectly do business with any client or customer of the Parent Parties or any of their respective Subsidiaries; and (ii) in the event that Sponsor or a Sponsor Director (or any Affiliate thereof) acquires knowledge of a potential transaction or matter that may be an opportunity for the Parent Parties or any of their respective Subsidiaries and Sponsor or any other Person, Sponsor and such Sponsor Director (and any such Affiliate) shall not have any duty (contractual or otherwise) to communicate or present such opportunity to the Parent Parties or any of their respective Subsidiaries, as the case may be, and, notwithstanding any provision of this Agreement to the contrary, shall not be liable to the Parent Parties, their respective Subsidiaries or their respective Affiliates or equity holders for breach of any duty (contractual or otherwise) by reason of the fact that Sponsor or such Sponsor Director (or such Affiliate thereof), directly or indirectly, pursues or acquires such opportunity for itself, directs such opportunity to another Person, or does not present such opportunity to the Parent Parties or any of their respective Subsidiaries; provided, that any such business, activity or transaction described in this Section 4.14 is not the direct result of Sponsor, its Affiliates or a Sponsor Director using Confidential Information in violation of Section 3.3 hereof. Notwithstanding anything to the contrary contained in this Section 4.14, any Sponsor Director may be excluded, by the members of the Board who are not Sponsor Directors, from any discussion or vote on matters in accordance with a conflicts of interest policy of the Board that is adopted by the Board in good faith and is applicable to all of the members of the Board.

Time is Money Join Law Insider Premium to draft better contracts faster.